Astria Therapeutics Azioni (NASDAQ: ATXS)

Astria Therapeutics (NASDAQ:ATXS) Azioni

ASTRIA THERAPEUTICS INC

Astria Therapeutics

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Astria Therapeutics Inc

Canaccord Genuity analyst Jason Tilchen maintains Super Group (SGHC) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) with a Buy and raises the price target from $12 to $14.

News

Price Target

Analyst Ratings

SGHC

Canaccord Genuity Maintains Buy on Super Group (SGHC), Raises Price Target to $14

WIIM

PSNY

Polestar Automotive Holding shares are trading higher after the company reported a year-over-year increase in Q1 retail sales results.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Keybanc analyst Steve Barger upgraded Federal Signal Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) from Sector Weight to Overweight and announced a $110 price target. Federal Signal shares closed at $89.56 on Friday. <a href="https://www.benzinga.com/quote/fss/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Argus Research analyst John Staszak upgraded the rating for Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) from Hold to Buy and announced a $40 price target. Wayfair shares closed at $32.79 on Friday. <a href="https://www.benzinga.com/quote/W/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson analyst Peter Heckmann upgraded ACI Worldwide, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIW#NASDAQ">ACIW</a>) from Neutral to Buy and maintained the price target of $60. ACI Worldwide shares closed at $46.56 on Friday. <a href="https://www.benzinga.com/quote/ACIW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst David Katz upgraded the rating for Marriott International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) from Hold to Buy and raised the price target from $226 to $303. Marriott International shares closed at $257.97 on Friday. <a href="https://www.benzinga.com/quote/MAR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Chris Schott upgraded Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) from Neutral to Overweight and raised the price target from $21 to $23. Teva Pharmaceutical shares closed at $16.93 on Friday. <a href="https://www.benzinga.com/quote/TEVA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying W stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="584" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12090618/image-124-1024x584.png" alt="" class="wp-image-911884" style="width:583px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12090618/image-124-1024x584.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12090618/image-124-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12090618/image-124-768x438.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12090618/image-124.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45342900/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-5">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

Markets

Trading Ideas

ACIW

TEVA

This Wayfair Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Guidance

UPLD

Upland Software Lowers FY2025 Sales Guidance from $231.50M-$255.50M to $209.50M-$227.50M vs $241.16M Est

New data in children under 5 years with achondroplasia showed treatment with VOXZOGO was associated with improvement in tibial bowing, a common cause of pain and impaired function&nbsp;
Data from the largest retrospective, multi-year observational study of more than 600 children and adults with hypochondroplasia found significantly higher rates of comorbidities, surgeries and overall doctor visits&nbsp;
SAN RAFAEL, Calif., May 12, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) today announced new data from studies of VOXZOGO&#xAE;&nbsp;(vosoritide), demonstrating meaningful impact on tibial bowing in children with achondroplasia and investigational early efficacy results in other skeletal conditions. The data were presented at the 2025 Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) in Copenhagen, Denmark and will be shared at the Pediatric Endocrine Society Annual Meeting (PES) in National Harbor, Maryland.

BMRN

Biomarin Pharma Announces New VOXZOGO Data Showing Tibial Bowing Improvement In Achondroplasia

Upland Software Sees Q2 Sales $50.300M-$56.300M vs $61.17M Est

FTRE

Fortrea Holdings shares are trading higher after the company reported better-than-expected Q1 financial results.

<figure class="table"> 
<table>
<tbody>
<tr>
<td>Citizens &amp; Northern Corporation ("C&amp;N") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZNC#NASDAQ">CZNC</a>), headquartered in Wellsboro, Pennsylvania, and Susquehanna Community Financial, Inc. ("SQCF") (OTCPK: SQCF), headquartered in West Milton, Pennsylvania, announced today that both companies' boards of directors have unanimously approved an agreement and plan of merger (the "Agreement") pursuant to which SQCF will merge with and into C&amp;N. C&amp;N is the bank holding company for Citizens &amp; Northern Bank ("C&amp;N Bank"), which operates 28 banking offices and one loan production office in Pennsylvania and New York. As of March 31, 2025, C&amp;N had consolidated assets of $2.6 billion. SQCF is the financial holding company for Susquehanna Community Bank ("Susquehanna"), which operates 7 banking offices in Central Pennsylvania. SQCF had assets of $598 million as of March 31, 2025. In connection with the merger of the holding companies, SQCF's bank subsidiary, Susquehanna, will be merged into C&amp;N Bank. The combined company will have approximately $3.2 billion in assets and will be the premier Pennsylvania community bank in the northern tier, central and southeast Pennsylvania. This strategic combination represents a substantial extension of legacy C&amp;N markets, creating additional scale in central Pennsylvania, while enhancing C&amp;N Bank's capacity to provide exceptional service and solutions to its clients across the Commonwealth. In addition, C&amp;N will further diversify its loan portfolio and funding base, increasing its resiliency and efficiency. The combined entity will successfully align its core values to ensure best-in-class service to the Pennsylvania community. A joint announcement of the transaction was made today by J. Bradley Scovill, President and CEO of C&amp;N, and David S. Runk, Chief Executive Officer of SQCF. Mr. Scovill stated, "This combination continues our strategic efforts to enter attractive markets through acquisition and leverages the strengths of two reputable community banks that share a similar culture and customer-first mindset." He continued, "We believe this is a great fit and we are pleased to welcome Dave and the SQCF team and customers to C&amp;N as we work together to expand our presence in Central Pennsylvania."&nbsp; SQCF shareholders will receive 0.80 shares of C&amp;N common stock for each share of SQCF common stock held, which based on C&amp;N's most recent closing price implies a price per share of $15.58 or $44.3 million in total consideration. Holders of SQCF common stock prior to the consummation of the merger will own approximately 13% of C&amp;N's common stock outstanding immediately following the consummation of the merger. The merger is expected to be approximately ~17% accretive to earnings per share in 2026, while resulting in single-digit tangible book value dilution at close, demonstrating a strong balance of strategic growth and financial discipline. &nbsp;</td>
</tr>
</tbody>
</table>
</figure>

CZNC

Citizens & Northern To Acquire Susquehanna Community Financial In All-Stock Merger Valued At $44.3M, With SQCF Shareholders Receiving 0.80 C&N Shares Per SQCF Share

Earnings

Earnings Beats

Upland Software Q1 Adj. EPS $0.23 Beats $0.17 Estimate, Sales $63.66M Beat $61.17M Estimate

UPXI

Upexi shares are trading higher after the company announced it purchased 326,347 units of Solana to be the largest publicly traded Solana treasury company.

Needham analyst Joseph Stringer maintains Vir Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) with a Buy and lowers the price target from $19 to $14.

Needham Maintains Buy on Vir Biotechnology, Lowers Price Target to $14

ORLA

Orla Mining shares are trading lower after the company reported worse-than-expected Q1 sales results.

Fueling R&amp;D of New Industrial Robots and Asia-Pacific Manufacturing Base Expansion
Shenzhen, China, May 12, 2025 (GLOBE NEWSWIRE) -- Lianhe Sowell International Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LHSW#NASDAQ">LHSW</a>) (the "Company"), a provider of machine vision products and solutions applied in a wide range of businesses across industries in China, today announced it received a letter of intent (the "LOI") from a large investment fund in China, Hangzhou Yuhang Economic Development Equity Investment Fund (the "Fund"), for a funding of no more than RMB200 million. The Company plans to apply the investment primarily to support the R&amp;D of its next-generation industrial robots and the construction of the Company's manufacturing base in Hangzhou, Zhejiang province. The LOI is non-binding and the final investment terms will be subject to a definitive agreement between the Company and the Fund.

LHSW

Lianhe Sowell International Group Receives LOI From Hangzhou Yuhang Economic Development Equity Investment Fund For Funding Of No More Than RMB200 Mln

Canaccord Genuity analyst Whitney Ijem maintains Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Buy and lowers the price target from $36 to $34.

RCKT

Canaccord Genuity Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $34

Vicon Industries, a subsidiary of Cemtrex Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) and a leading provider of advanced security and surveillance solutions, today announced that it has officially received the STQC certification from India's Ministry of Electronics and Information Technology (MeitY), marking a major milestone in the company's global expansion strategy.
With this certification, Vicon becomes one of the select few surveillance manufacturers to meet the stringent cybersecurity and quality standards under India's IoT Security Compliance for Surveillance Cameras Scheme (IoTSCS-ER). The designation enables Vicon to market and sell its certified products into India's regulated government, infrastructure, and smart city segments, sectors that are otherwise closed to non-certified providers.

Global

CETX

Cemtrex's Vicon Industries Secures STQC Certification From India's Ministry Of Electronics And Information Technology

Management

WEC Energy Group Appointed Michael Hooper Executive Vice President And Chief Operating Officer

Jim Cramer has raised concerns over the constitutionality of recent drug price controls, urging pharmaceutical companies to seek an injunction.
What Happened: &nbsp;CNBC&#8217;s Mad Money host, Cramer, in a post on X on Monday, argued that, unlike tariffs, drug price controls fall under the Commerce Clause of the Constitution and suggested they may not hold up under legal scrutiny. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Price controls are not like tariffs. They are covered by the Commerce Clause of the Constitution. These drug controls most likely will not stand. The drug companies should move for an injunction today, or they are really ill-advised
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1921870793585156494?ref_src=twsrc%5Etfw">May 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
This follows President Donald Trump's May 12, 2025, announcement to align U.S. drug prices with lower international rates—a move that triggered a decline in pharmaceutical stocks. Cramer's push for an injunction is a calculated effort to challenge the policy, citing federal overreach as a legal basis.
&#8220;The drug companies should move for an injunction today, or they are really ill-advised,&#8221; wrote Cramer.
SEE ALSO:&nbsp;<a href="https://benzinga.com/trading-ideas/movers/25/05/45339289/bitcoin-taps-105000-ethereum-steady-dogecoin-falls-as-us-announces-china-trade-deal-analyst-says-btc-in-for-a-price-discovery-uptrend-if-it-secures-a-weekly-close-above-this-lev" target="_blank" rel="noreferrer noopener">Bitcoin Taps $105,000, Ethereum Steady, Dogecoin Falls As US Announces China Trade Deal: Analyst Says BTC In For A &#8216;Price Discovery Uptrend&#8217; If It Secures A Weekly Close Above This Level &#8211; Grayscale B</a>
Why It Matters: Trump&#8217;s <a href="https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80">announcement</a>, described as the "most consequential executive order" in U.S. history, intends to implement a "Most Favored Nations" policy. This policy requires pharmaceutical companies to charge U.S. consumers no more than the lowest price they offer for the same drug in any other country.
Trump&#8217;s move is expected to slash prescription drug prices by<a href="https://www.benzinga.com/general/health-care/25/05/45339399/trump-says-prescription-drug-prices-set-to-drop-by-30-to-80-almost-immediately-thanks-to-most-favored-nation-plan-mark-cuban-urges-president-to-force-tran"> 30% to 80%</a> &#8216;almost immediately.&#8217; However, Cramer&#8217;s argument suggests that this policy may face legal challenges. In another post on Truth Social on Monday, Trump specified that he would lower drug prices by 59%. 
Meanwhile, billionaires Mark Cuban and Bill Ackman have shown support for Trump&#8217;s executive order. Cuban has also <a href="https://www.benzinga.com/markets/equities/25/05/45344525/mark-cuban-slams-charlie-kirk-over-drug-price-debate-says-pbms-not-big-pharma-are-the-real-villains-for-your-companyask-your-pbm-for-a-list-of-claims">pointed out</a> that Pharmacy Benefit Managers (PBMs), not Big Pharma, are the main culprits behind high drug prices due to their opaque pricing practices and market dominance, urging Trump to force transparency.
Notably, the U.S. pays nearly three times more for prescription drugs than other developed nations and Trump's first-term attempt to lower prices was blocked by the courts.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/25/05/45339966/bitcoin-creator-satoshi-nakamotos-estimated-wealth-crosses-bill-gates-amid-apex-cryptos-sharp-rebound" target="_blank" rel="noreferrer noopener">Bill Gates Left Behind By Satoshi Nakamoto: Bitcoin Creator&#8217;s Wealth Now Eclipses That Of Microsoft Co-Founder Amid Crypto&#8217;s Sharp Rebound</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Economics

General

Jim Cramer Says 'Price Controls Are Not Like Tariffs' — Urges Drugmakers To Challenge Trump's Plan With 'Injunction'

Comstock Holding Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHCI#NASDAQ">CHCI</a>) reported quarterly earnings of $0.15 per share. This is a 66.67 percent increase over earnings of $0.09 per share from the same period last year. The company reported $12.64 million in sales this quarter. This is a 18.81 percent increase over sales of $10.64 million the same period last year.

CHCI

Comstock Holding Co Q1 EPS $0.15 Up From $0.09 YoY, Sales $12.64M Up From $10.64M YoY

Canaccord Genuity analyst Richard Close maintains Progyny (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>) with a Hold and lowers the price target from $23 to $21.

PGNY

Canaccord Genuity Maintains Hold on Progyny, Lowers Price Target to $21

Contracts

BOSC

BOS Better Online Solutions Secures Order For Automated End-Of-Line Systems, Combined Value $270K

Press Releases

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress

Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference

Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology

Comments

Astria Therapeutics

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO